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BACKGROUND: Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence
of brain metastases in patients with HER-2 positive (þve) advanced breast cancer .We have retrospectively evaluated the outcome
of patients with HER-2þve locally advanced (LA) or metastatic breast cancer (MBC) who continued T beyond PD, treated in our
unit.
METHODS: All HER-2þve patients on our prospectively maintained database with LA or MBC who received T beyond PD after
adjuvant or one line of T for advanced disease were assessed for response and outcome. From the timepoint of T continuation
beyond PD, we calculated the overall disease control rate, time to progression (TTP), and overall survival (OS).
RESULTS: One hundred and fourteen patients with HER-2þve LA or MBC treated with T beyond PD were identified. The main site of
disease was visceral in 84 (74%) patients. Seventy-six (66%) had one line of chemotherapy before continuation of T beyond PD and
21 (19%) had two or more. Post-progression, 66 (58%) received T combined with chemotherapy. Of the 93 (82%) patients with
documented clinical or radiological response evaluation, 67 (59%) were considered as having stable disease or better. The median
TTP was 24 weeks (95% CI: 21–28) and the median OS was 19 months (95% CI: 12–24).
CONCLUSION: Our results from an unselected group of patients provide additional evidence that continuation of T beyond PD is
of clinical benefit.
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Development of resistance to treatment remains an important
problem in HER2-positive breast cancer. At the point of disease
progression (PD) on trastuzumab, there currently remains debate
as to whether it should be continued alongside a change in other
systemic therapy, switched/added to an alternative anti-HER2-
targeted agent, or discontinued altogether. In preclinical studies, it
was noted that continuation of trastuzumab had some ongoing
effect against cell proliferation, with rapid tumour re-growth
observed when it was subsequently withdrawn (Pietras et al, 1998;
Pegram et al, 2004; Fujimoto-Ouchi et al, 2010). Randomised
clinical data to support this preclinical work has previously been
lacking, with evidence generally coming from retrospective
analyses (Stemmler et al, 2005; Bartsch et al, 2007; Menard et al,
2008).
However, a recent prospective randomised phase III study
(GBG26) showed benefit for trastuzumab continuation alongside
capecitabine compared with capecitabine alone. Continuation was
associated with a statistically significant improvement in time to
progression (TTP), overall response rate (ORR), and a trend
towards improved overall survival (OS) (Von Minckwitz et al,
2009). A second study (EGF100151) has looked at the possibility of
switching at PD from trastuzumab to an alternative anti-HER2-
targeted therapy, lapatinib. Women with HER2-positive breast
cancers, which had progressed following treatment with anthra-
cyclines, taxanes, and trastuzumab, were randomised to either
capecitabine alone or capecitabine plus lapatinib with the primary
end point defined as progression-free survival (PFS). The results
showed statistically significant superiority of the combination
therapy arm in terms of PFS, and a trend towards improved
survival (Geyer et al, 2006).
Furthermore, results from a recent randomised phase II study
(EGF104900) of lapatinib with or without trastuzumab, in a heavily
trastuzumab pretreated population, showed that the combination
performed better than the single-agent approach. The authors
concluded that dual HER2 blockade is effective and offers the
option of treatment without chemotherapy and its side effects
(Blackwell et al, 2010).
Despite a growing body of evidence to support the continuation
of trastuzumab at PD, NICE guidance in the UK states that ‘For
patients who are receiving treatment with trastuzumab for
advanced breast cancer, discontinue treatment with trastuzumab
at the time of disease progression outside the central nervous
system. Do not discontinue trastuzumab if disease progression is
within the central nervous system alone’ (NICE Guidance, 2009).
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sPractising oncologists in the United Kingdom have therefore
found that they can no longer obtain funding for trastuzumab
beyond progression, a practice that was previously commonplace.
In contrast, outside of the United Kingdom, the international
breast cancer community continue to prescribe anti-HER2-
targeted therapies alongside multiple lines of systemic treatment
in this patient population.
On this ground, we considered it timely to assess retrospectively
the clinical efficacy and safety of our practice to continue
trastuzumab beyond progression.
PATIENTS AND METHODS
The study population comprised patients with metastatic or locally
advanced HER2-positive breast cancer who continued trastuzumab
beyond PD at the Royal Marsden Hospital between January 2001
and December 2008. All patients who progressed after one line of
trastuzumab for advanced disease were included regardless of the
number of previous non-trastuzumab therapies in the metastatic
setting. Those who had received adjuvant trastuzumab were also
eligible if they had relapsed during or within 12 weeks of
completing adjuvant trastuzumab, and subsequently continued it
into the advanced-disease setting.
Eligible patients with HER2-positive disease based on over-
expression as detected by immunohistochemistry (3þ staining) or
amplification by fluorescent in situ hybridisation (FISH) were
identified from a prospectively maintained Royal Marsden
Hospital breast research database, and from an electronic hospital
pharmacy database of all dispensed doses of trastuzumab.
Relevant data were subsequently collected from individual
electronic patient records. These included demographic data,
information regarding the date of initial breast cancer diagnosis,
date of metastatic or locally advanced disease, sites of metastases,
ER/PgR status, and details of all previous and subsequent lines of
therapy received.
Information was collected on the date trastuzumab was started,
details of concurrent chemotherapy/hormone therapies, date of
first documented progressive disease, changes to concurrent
therapy at that point, and date of next progression after
trastuzumab continuation.
Response data were collected from imaging reports where
available and serial clinical assessments.
Discontinuation of trastuzumab due to cardiac toxicity includ-
ing reduced left ventricular ejection fraction was also recorded
from case records.
Study end points
The primary end point of the study was TTP from the timepoint of
trastuzumab continuation after PD. Secondary end points were
overall disease control rate defined as patients achieving clinically
or radiologically stable disease (SD) for X3 months or better
and OS.
In addition to our overall analysis, we also performed a
subgroup analysis of those patients whose initial trastuzumab
therapy was either in the first-line metastatic setting or had
relapsed during, or within 12 weeks of completing adjuvant
trastuzumab, and subsequently continued it into the advanced-
disease setting (a population comparable to that of the GBG26
study).
Statistical analysis
Time to progression on continuation of trastuzumab beyond
progression was calculated by the Kaplan–Meier method and was
measured from the date of first progression on trastuzumab until
the next PD in any site. Patients were censored at last follow-up or
at death in the absence of PD.
Overall survival was measured from the date of first progression
until death from any cause and was censored at last follow-up.
A Cox proportional hazards model was applied to adjust for
prognostic factors that influenced TTP, including age, ER/PgR
status, sites of disease, adjuvant chemotherapy vs not, previous
lines of chemotherapy for metastatic disease, and type of treatment
combined with trastuzumab for metastatic disease (initial and
beyond progression).
The study proposal was reviewed and approved by our
Institutional Audit Committee.
RESULTS
Patient demographics
Through our initial database screening, 128 patients were
identified who appeared eligible for inclusion in the study.
However, 14 of these patients were subsequently excluded from
the data collection (see Figure 1) leaving a total of 114 patients. At
the time of analysis, 35 patients (31%) were still alive with a
median follow-up of 20 months. The main site of disease was
visceral in 84 patients (74%), including 37 patients (32%) with
central nervous system involvement. Twenty-six patients (23%)
developed brain metastases while on first-line trastuzumab and
continued trastuzumab beyond progression in the brain. Thirty
patients (26%) had soft tissue and/or bone metastases only. Fifty-
nine patients (52%) had received adjuvant chemotherapy, whereas
only 13 (11%) had received adjuvant trastuzumab. Other baseline
information and previous and subsequent lines of therapy are
outlined in Table 1.
At the point of continuing trastuzumab beyond PD, 12 patients
(11%) received this in combination with taxanes, 32 patients (28%)
with capecitabine, and 22 patients (19%) with vinorelbine. Another
four patients (4%) continued trastuzumab alongside endocrine
therapy and 44 patients (38%) continued trastuzumab alone. Of
these 44 patients, 29 (25%) received also some form of radio-
therapy. All but two patients of the 26 who developed brain
Initial database screen
N=128
Confirmed not to have continued
trastuzumab beyond progression: N=7
Patients receiving treatment elsewhere /
information not available: N=3
Not progressed on trastuzumab by 
31 December 2008: N=2
Second primary cancer making assessment
of metastatic disease impossible: N=1
Adjuvant trastuzumab completed >12
weeks before to subsequent progression: N=1
Final number of eligible patients
N=114
Figure 1 Identification of eligible patients.
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smetastases while on first-line trastuzumab received brain radio-
therapy alongside continuation of trastuzumab.
Seven (6%) patients received lapatinib as a subsequent line of
therapy following the second progression on trastuzumab.
Eighty-one (71%) patients were found to match the GBG26 study
population and their demographics and previous and subsequent
therapies are shown in Table 2.
Outcome
The median TTP for all patients was 24 weeks (95% CI: 21–28
weeks) and the median OS was 19 months (95% CI: 12–24
months). The median TTP did not differ (TTP: 24 weeks; 95% CI:
16–32) for the patients who developed brain metastases and
continued trastuzumab beyond progression in the brain.
No prognostic factors were identified to predict for longer TTP.
Information regarding response after continuation of trastuzu-
mab beyond PD was not available for 21 (18%) of the patients. Of
the 93 patients (82%) with documented clinical (n¼16) or
radiological (n¼77) response evaluation (Table 3), 67 (59%) were
considered to have SD or better and 26 (23%) as having PD. It was
not possible to differentiate between partial response and SD as
this was a retrospective study and scan reporting was not always
performed according to the RECIST criteria.
In the 81 patient subgroup analysis, overall disease control was
achieved in 50 (61%) patients, the median TTP was 25 weeks
(95% CI: 18–33 weeks), and the median OS was 22 months (95%
CI: 17–27 months) (Table 4).
Only six (5%) patients overall had to discontinue trastuzumab
secondary to decline in LVEF. No cardiac deaths were observed.
Table 2 Clinical characteristics of the 81 patients with HER2+ve locally
advanced or MBC (same patient inclusion criteria as in the GBG26 study)
Median age (range) 55 (29–84)
Hormone receptor status +ve (%)  ve (%) nk (%)
ER 38 (47) 43 (53) —
PgR 11 (13.5) 53 (65.5) 17 (21)
Metastatic site Number of patients (%)
CNS 28 (34.5)
Liver 42 (52)
Lung 24 (30)
Bone 48 (59)
Soft tissue 18 (22)
Nodes 30 (37)
Any visceral/CNS 63 (78)
Non-visceral 18 (22)
Adjuvant chemotherapy 59 (73)
Anthracycline based 39 (48)
Taxane based 12 (15)
Other 8 (10)
Adjuvant trastuzumab 7 (9)
Previous therapy with trastuzumab
Trastuzumab alone 11 (13.5)
Trastuzumab plus chemotherapy 66 (81.5)
Anthracycline based 4 (5)
Taxane based 41 (51)
Vinorelbine 15 (18.5)
Capecitabine 6 (7)
Trastuzumab plus endocrine therapy 4 (5)
Duration of previous trastuzumab (weeks)
Median (range) 39 weeks (5 weeks–38 months)
o12 4
12–24 16
424 61
Treatment at progression
Trastuzumab alone 11 (13.5)
Trastuzumab plus chemotherapy 44 (54)
Taxane based 9 (11)
Capecitabine 21 (26)
Vinorelbine 14 (17)
Trastuzumab plus endocrine therapy 2 (2.5)
Trastuzumab plus radiotherapy 24 (30)
Abbreviations: CNS¼central nervous system; ER¼oestrogen receptor; HER2¼human
epidermal growth factor receptor 2; MBC¼metastatic breast cancer; PgR¼
progesterone receptor.
Table 1 Clinical characteristics of the 114 patients with HER2+ve locally
advanced or MBC
Median age (range) 56 (28–85)
Hormone receptor status +ve (%)  ve (%) nk (%)
ER 58 (51) 56 (49) —
PgR 17 (15) 70 (61) 27 (24)
Metastatic site Number of patients (%)
CNS 37 (32)
Liver 61 (53.5)
Lung 35 (31)
Bone 66 (58)
Soft tissue 31 (27)
Nodes 42 (37)
Any visceral/CNS 84 (74)
Non-visceral 30 (26)
Adjuvant chemotherapy 59 (52)
Anthracycline based 39 (34)
Taxane based 12 (11)
Other 8 (7)
Adjuvant trastuzumab 13 (11)
Number of previous lines of chemotherapy (before trastuzumab beyond progression)
0 17 (15)
1 76 (66)
2 18 (16)
3 3 (3)
Previous therapy with trastuzumab
Trastuzumab alone 20 (18)
Trastuzumab plus chemotherapy 86 (75)
Anthracycline based 4 (4)
Taxane based 53 (46)
Vinorelbine 22 (19)
Capecitabine 7 (6)
Trastuzumab plus endocrine therapy 8 (7)
Duration of previous trastuzumab (weeks)
Median (range) 39 weeks (3 weeks–38 months)
o12 11
12–24 21
424 82
Treatment at progression
Trastuzumab alone 15 (13)
Trastuzumab plus chemotherapy 66 (58)
Taxane based 12 (11)
Capecitabine 32 (28)
Vinorelbine 22 (19)
Trastuzumab plus endocrine therapy 4 (4)
Trastuzumab plus radiotherapy 29 (25)
Abbreviations: CNS¼central nervous system; ER¼oestrogen receptor; HER2¼human
epidermal growth factor receptor 2; MBC¼metastatic breast cancer; PgR¼progesterone
receptor.
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sDISCUSSION
The findings of this study support a growing body of evidence that
is now consistently showing improved response rates and TTP
when trastuzumab is continued beyond PD in HER2-positive
advanced breast cancer (Stemmler et al, 2005; Bartsch et al, 2007;
Fabi et al, 2008; Von Minckwitz et al, 2009; Blackwell et al, 2010).
We recognise that our study is limited by its retrospective nature
and the lack of a comparable control group who did not continue
trastuzumab at progression. Nevertheless, in this unselected group
of patients, many of whom had been heavily pretreated,
continuation of trastuzumab was associated with a clinically
meaningful median TTP of 24 weeks.
Direct comparison of this study with other studies cannot be
made. However, our results seem to compare favourably with the
capecitabine-alone arm of the EGF100151 study (median TTP 4.4
months), (Geyer et al, 2006), suggesting efficacy of continued
trastuzumab in our study population.
In the GBG26 study, the results are generally superior with the
capecitabine-alone arm having a median TTP of 5.6 and the
combination therapy arm having a median TTP of 8.2 months
(Von Minckwitz et al, 2009). This difference likely reflects that
eligible patients in the German study were only permitted to have
one previous line of chemotherapy. In addition, in our study
population many patients continued trastuzumab alongside
palliative radiotherapy or change in hormone therapy, rather than
with chemotherapy. It is worth noting here that it has been
previously shown that trastuzumab does have particular synergy
when combined with chemotherapy (Arteaga et al, 1994; Pegram
et al, 1998, 1999).
Our results are entirely concordant with other retro-
spective analyses of trastuzumab continuation in this patient
population (Stemmler et al, 2005; Bartsch et al, 2007; Fabi et al,
2008; Menard et al, 2008; Extra et al, 2010), including patients
who developed brain metastases while on trastuzumab and
continued trastuzumab beyond progression in the brain
(Park et al, 2009). These studies share the common limitations
of a retrospective approach. However, it seems highly unlikely
that there will be further prospective, randomised studies
examining the specific role of trastuzumab combined with
second-line chemotherapy for women who have progressed on
trastuzumab.
The international oncological community has already adopted
the practice of continuing trastuzumab beyond PD. In contrast,
practising oncologists in the UK are now finding that they can no
longer obtain funding for trastuzumab beyond progression
because of the NICE recommendation, which was based on the
absence of published, level 1 evidence showing an improved OS
associated with continuation of trastuzumab.
Further studies with novel anti-HER-2-targeted therapies, such
as pertuzumab, TDM-1, and Neratinib, continue to explore the
value of multiple lines of anti-HER2 therapies in this subpopula-
tion of breast cancer patients (Baselga et al, 2010; Burstein et al,
2010; Burris et al, 2011). However, until these novel therapies
establish their role, continuation of trastuzumab beyond progres-
sion should remain an option in the management of patients with
HER2-positive advanced breast cancer. Furthermore, NICE should
consider re-evaluating its current recommendation to ensure that
breast cancer practice in the UK does not become significantly
discordant with both the published evidence and the international
oncological community.
In conclusion, our study supports the positive results and good
safety data shown in previous studies. Continuation of trastuzu-
mab beyond PD in women with HER2-positive advanced breast
cancer is of meaningful clinical benefit and should remain a
treatment option for this patient population.
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